Molecular Health announced today it has been granted a patent in Europe entitled “Tissue Protective Erythropoietin Receptor”. This latest patent supports Molecular Health’s discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

Original post:
Molecular Health granted European patent for novel Erythropoietin receptor

Scroll to Top